Antibiotic Resistance Program Launched in Europe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Antibiotic Resistance Program Launched in Europe



The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the launch of a €223.7-million ($276.5 million) program to tackle antimicrobial resistance and speed up the development of new antibiotics. The program was launched by the Innovative Medicines Initiative (IMI), a public–private partnership, and builds on the European Commission’s Action Plan against the rising threats from Antimicrobial Resistance, which was launched in November 2011.

The program will bring together leading academics and five major pharmaceutical companies. The IMI has issued a call for proposals and has set aside a budget of up to €223.7 million ($276.5 million) in funding, with €109 million ($134.8 million) coming from the IMI and a further €114.7 million ($141.8 million) coming from contributions by participating EFPIA companies.

Michael Goldman, executive director of the IMI, said in a statement, “This is a historic opportunity for Europe to overcome a public health problem which threatens millions of lives worldwide. For researchers in universities, hospitals and small and medium-sized enterprises it is also a unique opportunity to speed up their research in the area of antimicrobial resistance, as the collaboration will give them access to the knowledge and expertise of the pharmaceutical industry.”

According to the IMI, antibacterial drug development is no longer a financially viable option for pharmaceutical companies. As well as scientific challenges and complex regulatory requirements, the cost of developing an antibiotic outweighs the potential returns on investment.

The IMI’s program is expected to use approximately €600 million in funding over the next seven years. Initial projects will focus on building and training networksof researchers, facilitating and increasing the exchange of research data, and improving the efficiency of clinical trials.

Richard Bergström, director-general of EFPIA said, “Our researchers and the scientific community have realized that we can only deal with this urgent threat by working together and pooling our knowledge.... by co-funding clinical trials, policy makers in Europe have created a strong incentive for companies and investors to come back to this field of research.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here